T1	intervention 0 46	Pegylated liposomal doxorubicin plus docetaxel
T2	total-participants 716 719	751
T3	control 747 756	docetaxel
T4	control-participants 773 776	373
T5	intervention-participants 848 851	378
T8	outcome 1133 1143	median TTP
T10	outcome 1270 1272	OS
T15	outcome 1360 1387	grade 3 or 4 adverse events
T16	iv-bin-percent 1402 1405	78%
T17	cv-bin-percent 1408 1411	72%
T18	outcome 1445 1463	hand-foot syndrome
T19	iv-bin-percent 1465 1468	24%
T20	cv-bin-percent 1471 1473	0%
T21	outcome 1479 1499	mucositis/stomatitis
T22	iv-bin-percent 1501 1504	12%
T23	cv-bin-percent 1507 1509	1%
T24	outcome 1576 1649	left ventricular ejection fraction decreases and congestive heart failure
T25	iv-bin-percent 1667 1669	5%
T26	cv-bin-percent 1674 1676	1%
T6	outcome 1237 1240	ORR
T9	outcome-Measure 944 969	time to progression (TTP)
T11	cv-cont-median 1149 1152	7.0
T12	iv-cont-median 1156 1166	9.8 months
T13	cv-bin-percent 1246 1249	26%
T14	iv-bin-percent 1253 1256	35%
T7	outcome-Measure 997 1018	overall survival (OS)
T27	outcome-Measure 1020 1049	objective response rate (ORR)
T28	outcome-Measure 1051 1067	cardiac toxicity
T29	outcome-Measure 1073 1079	safety
